Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, ...

The Council for the Indian School Certificate Examinations (CISCE) has released the ISC Computer Science (Subject Code - 868) for the Year 2027 evaluation cycle. It is designed specifically to make ...

Mirendil, founded by two ex-Anthropic researchers, raised $200M at a $1bn valuation to sell self-improving AI research to everyone.

Don't worry, this post is spoiler-free.

Just over a week ago, I attended a major artificial intelligence conference in Zhongguancun, Beijing’s bustling high-tech ...

Blake Crouch wrote a popular science-fiction thriller novel that is just screaming for a Hollywood adaptation. So, what's the ...

Google DeepMind CEO Demis Hassabis warns humanity is on the cusp of Artificial General Intelligence, potentially within four years, urging immediate preparation. He views current AI agents as a ...

That brings us to Recursion Pharmaceuticals (RXRX +3.86%), a biotech company specializing in drug discovery using artificial intelligence (AI). At least one notable name in the investing world thinks ...

This was largely due to news from a rival clincal-stage biotech. Late on Friday, U.K.-based Biodexa announced it had launched a phase 3 clinical trial of its eRapa, an investigational drug that ...

Recursion Pharmaceuticals (RXRX) shares soared 5.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing hands than in a normal session.